A Closer Look at 9 Analyst Recommendations For CG Oncology

9 analysts have expressed a variety of opinions on CG Oncology CGON over the past quarter, offering a diverse set of opinions from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Analysts have recently evaluated CG Oncology and provided 12-month price targets. The average target is $68.33, accompanied by a high estimate of $75.00 and a low estimate of $50.00. This current average has decreased by 1.92% from the previous average price target of $69.67.

Breaking Down Analyst Ratings: A Detailed Examination

In examining recent analyst actions, we gain insights into how financial experts perceive CG Oncology. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CG Oncology. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CG Oncology compared to the broader market.
• Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of CG Oncology's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on CG Oncology analyst ratings.

Discovering CG Oncology: A Closer Look

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Unraveling the Financial Story of CG Oncology

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Revenue Growth: Over the 3 months period, CG Oncology showcased positive performance, achieving a revenue growth rate of 172.68% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: CG Oncology's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -3200.76%, the company may face hurdles in effective cost management.

Return on Equity (ROE): CG Oncology's ROE excels beyond industry benchmarks, reaching -7.6%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): CG Oncology's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -4.35%, the company showcases efficient use of assets and strong financial health.

Debt Management: With a below-average debt-to-equity ratio of 0.0, CG Oncology adopts a prudent financial strategy, indicating a balanced approach to debt management.

What Are Analyst Ratings?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.